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Objectives: HIV-1 integrase inhibitors are recommended as first-line therapy by WHO, though efficacy and
resistance data for non-B subtypes are limited. Two recent trials have identified the integrase L74I mutation to
be associated with integrase inhibitor treatment failure in HIV-1 non-B subtypes. We sought to define the preva-
lence of integrase resistance mutations, including L74I, in West Africa.
Methods: We studied a Nigerian cohort of recipients prior to and during receipt of second-line PI-based therapy,
who were integrase inhibitor-naive. Illumina next-generation sequencing with target enrichment was used
on stored plasma samples. Drug resistance was interpreted using the Stanford Resistance Database and the
IAS-USA 2019 mutation lists.
Results: Of 115 individuals, 59.1% harboured CRF02_AG HIV-1 and 40.9% harboured subtype G HIV-1. Four
participants had major IAS-USA integrase resistance-associated mutations detected at low levels (2%–5%
frequency). Two had Q148K minority variants and two had R263K (one of whom also had L74I). L74I was
detected in plasma samples at over 2% frequency in 40% (46/115). Twelve (26.1%) had low-level minority
variants of between 2% and 20% of the viral population sampled. The remaining 34 (73.9%) had L74I present at
>20% frequency. L74I was more common among those with subtype G infection (55.3%, 26/47) than those with
CRF02_AG infection (29.4%, 20/68) (P = 0.005).
Conclusions: HIV-1 subtypes circulating in West Africa appear to have very low prevalence of major integrase
mutations, but significant prevalence of L74I. A combination of in vitro and clinical studies is warranted to under-
stand the potential implications.
Introduction
Drug resistance is common amongst individuals with virological
failure (VF) of first-line NNRTI-based ART regimens under condi-
tions of infrequent viral load monitoring.1,2 Second-generation
integrase inhibitors such as dolutegravir are now recommended
for first-line HIV treatment regimens,3 following an increase in
pre-treatment drug resistance to NNRTI-based regimens globally,
including Nigeria.4–6 A number of studies have shown that
pre-existing integrase resistance,27 as assessed using standard
lists of mutations derived largely from subtype B data, is rare
across globally dominant subtypes.7,8
As dolutegravir-based ART is rolled out globally, a wider range
of HIV-1 subtypes will be exposed and the effects of integrase
polymorphisms and subtype diversity on the clinical efficacy of
these agents are currently not well understood. Although poly-
morphisms are generally thought to have little impact on viral
phenotype, this is not always true, particularly when comparing B
with non-B subtypes.9 A good example is G118R in integrase, a
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polymorphism that confers significant integrase strand transfer
inhibitor (INSTI) resistance.10
Two recent Phase 3 trials of the long-acting injectable second-
generation integrase inhibitor cabotegravir and the injectable
second-generation NNRTI rilpivirine, FLAIR in ART-naive partici-
pants and ATLAS in ART-experienced participants,11 found non-
inferiority of long-acting injectables compared with oral therapy.
However, three participants treated with the long-acting injectable
drug experienced VF. All three were infected with HIV-1 subtype
A1 and were from Russia. All three had L74I in integrase at both
baseline and at VF. At VF the major integrase mutation Q148R
occurred in two and G140R in one.11
L74 is in the catalytic core domain, which carries out the inte-
grase strand transfer reaction. It is part of a hydrophobic cluster of
residues that includes resistance-associated mutations T97 and
F121 near the active site.12 In the Stanford Resistance Database
(https://hivdb.stanford.edu)13 L74I is reported to be observed in 3%–
20%, depending on subtype. The L74M variant has been included as
a minor mutation for the first-generation INSTI raltegravir in the
IAS-USA drug resistance mutations list (https://www.iasusa.org/wp-
content/uploads/2019/09/27-3-111.pdf), but the L74I variant is not
recognized as a resistance-associated mutation.14 The Stanford
Resistance Database includes L74I in combination with other inte-
grase mutations.13 L74I and L74M are assessed together and com-
bined prevalences are often reported7 as they have both been
shown to enhance integrase inhibitor resistance when present with
major INSTI mutations. A recent report suggested that methionine
at residue 74 was in closer proximity to T97 and F121 as compared
with leucine at position 74 in a modelled subtype C integrase and, of
note, L74F was found to contribute to high-level dolutegravir resist-
ance when combined with major mutations G140S and Q148H.15
We studied a Nigerian cohort of people living with HIV in whom
the West African CRF02_AG and G subtypes account for the majority
of infections.16 We aimed to determine the prevalence of INSTI resist-
ance, as well as the prevalence and dynamics of L74I, in this setting.
Patients and methods
Study participants were selected from an HIV-positive second-line treat-
ment cohort at the University of Abuja Teaching Hospital (UATH) in Abuja,
Nigeria. Informed consent was obtained from all participants and ethics ap-
proval for virological testing was obtained from the Nigeria National
Research Ethics Committee of Nigeria (NHREC/01/01/2007). Ethics approval
was also obtained from the ethics board of UCL, UK. The Institute of Human
Virology Nigeria (IHVN) database was used to identify people living with HIV
(PLWH) aged >15 years who had attended UATH and received a first-line
ART regimen of two NRTIs and one NNRTI, followed by a second-line ART
regimen of two NRTIs and one PI (lopinavir or atazanavir). Participants were
included in the study if they: (i) had experienced first-line VF, defined as HIV
RNA >1000 copies/mL at least 6 months after first-line ART initiation; (ii) had
a stored plasma sample that was obtained during first-line VF, prior to
switching to a second-line regimen; and (iii) had a whole HIV genome se-
quence successfully generated from the first-line VF sample. If participants
had subsequent stored plasma samples from first-line or second-line VF
these were also included where possible. CD4 cell count and HIV-1 RNA
quantitation were performed at the IHVN laboratories. For next-generation
sequencing, manual nucleic acid extraction was done at University College
London (UCL) using the QIAamp Viral RNA Mini Kit, (QIAGEN, Hilden,
Germany) with a plasma input volume of 0.5–1.5 mL. The first strand of
cDNA was synthesized using SuperScript IV reverse transcriptase
(Invitrogen, Waltham, MA, USA), followed by NEBNext second-strand cDNA
synthesis (E6111, New England Biolabs GmbH, Frankfurt, Germany). Sample
libraries were prepared as per the SureSelectXT automated target enrich-
ment protocol (Agilent Technologies, Santa Clara, CA, USA) with in-house
HIV baits. Whole-genome deep sequencing was performed using the
Illumina Miseq platform (San Diego, CA, USA).
Poor-quality reads were identified and removed using TrimGalore
v0.6.4.17 A set of 170 HIV-1 subtypes/circulating recombinant forms (CRFs)
were downloaded from the Los Alamos database (https://www.hiv.lanl.gov)
and the trimmed reads were compared with this database using BLAST to
identify the closest reference.18 Trimmed reads were mapped to the closest
reference genome using the Burrows–Wheeler aligner.19 Duplicate reads
were removed from the BAM files with Picard (http://broadinstitute.github.io/
picard) and a consensus sequence of nucleic acids with a minimum whole-
genome coverage of 20% was generated with BCFtools using a 50%
threshold.20 Consensus sequences were used to determine the codon usage
at integrase position 74 and subtype was assigned using REGA v3.0.21 The
presence and frequency of IAS-USA resistance-associated mutations in inte-
grase, in addition to L74I, was assessed. Mutations were included if they
were present at over 2% frequency within the read mixture at that position
and present on at least two reads. A threshold of 2% is supported by a study
evaluating different analysis pipelines, which reported fewer discordances
over this cut-off.22 In addition, inspection of the mean read depth across
regions of interest in the present study showed that a cut-off of <2% would
not include sufficient reads to provide accurate assumptions regarding re-
sistance mutations. An in-house custom script was used to identify SNPs at
each position by BLAST analysis of individual HIV pol against the HXB2 refer-
ence genome. SNPs were identified and then translated to codons across all
regions. Statistical analysis was performed in Stata v13.1 (StataCorp LLC,
College Station, TX, USA) and SAS v9.4 (SAS Institute, Cary, NC, USA).
Results
Overall, 115 participants had a total of 163 plasma samples that
yielded HIV pol sequences. Two participants had a sample obtained
prior to receiving any ART, 72 participants had samples from first-
line ART only (two had multiple first-line samples), 14 participants
had samples from second-line ART only (four had multiple second-
line samples) and 27 participants had samples obtained during
first-line and second-line ART (Table S1, available as Supplementary
data at JAC Online). The median sequencing coverage of all sam-
ples at the whole-genome level was 583 reads per base (IQR = 136–
1313), 595 (IQR = 125–1324) for the pol gene and 735 (IQR = 162–
1593) for the integrase L74 codon. Detailed coverage data are
shown in Table S2. Four participants had major IAS-USA integrase
resistance-associated mutations detected at low levels (2%–5%
frequency). Two had Q148K and two had R263K minority variants
(one of whom also had L74I). Another six participants had minor
IAS-USA integrase resistance-associated mutations. Four had T97A
[this was the consensus in three of them and a minority variant in
one (who also had L74I)], another participant had an E138K minor-
ity variant and another had a G140A minority variant. The most
common integrase polymorphism was E157Q, which was detected
in 12 participants (6 of these also had L74I).
Forty-six (40%) of the participants had L74I detected at >2%
frequency in at least one plasma sample. The participant charac-
teristics of those with and without an L74I mutation were similar,
with an overall median age of 30 years, two-thirds were female
and the median CD4 cell count at first-line VF was 142 cells/mm3
(IQR = 64–246) (see Table 1).
Considering the first timepoint at which L74I was detected for
each participant, the median frequency of L74I was 90.6%
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(IQR = 17.8–98.7). Twelve of the 46 participants (26.1%) had
low-level minority variants of between 2% and 20% of the viral
population sampled (seven with 2%–5% frequency, four with 5%–
10% and one with 10%–20%). The remaining 73.9% (34/46) had
L74I present at >20% frequency (the usual Sanger sequencing
threshold of detection). This comprised 4 participants with 20%–
50% frequency, 6 with 50%–90% frequency and 24 in whom L74I
was fixed at >90% frequency at that position. There was a subtype
difference in L74I prevalence, with 55.3% (26/47) of participants
with subtype G infection having the L74I mutation detected in
at least one plasma sample, compared with 29.4% (20/68) of
those with CRF02_AG infection (P = 0.005). There was a similar fre-
quency of L74I among the subtypes, with a median frequency of
93.0% (IQR = 26.9–99.0) in CRF02_AG and 89.2% (IQR = 8.1–98.2)
(P = 0.62) in subtype G.
Thirty-three participants had more than one plasma sample
and therefore intra-host changes could be evaluated. Eight partici-
pants had L74I as the majority allele (>85% frequency) in every
sample (Table 2). Four had low-level minority variants of less than
10% frequency and in two of these L74I was not detected in the
preceding plasma samples. Two participants had reversion to low
(<2%) or no L74I in subsequent samples.
Codon usage at the integrase 74 position was examined using
consensus sequences. All sequences with L74I at consensus (27%,
31/115) had the trinucleotide ATA at this position. The remaining
consensus sequences were all L74L. The trinucleotides CTG or TTG
were the consensus codon in 60% (69/115), requiring two nucleo-
tide changes to result in an amino acid substitution from leucine to
isoleucine, and 13% (15/115) had either TTA or CTA, requiring only
one nucleotide change to mutate to L74I. Synonymous changes in
codon usage were noted in two of the participants from whom
more than one sample was available. One changed from TTA to
CTA (both requiring one further nucleotide substitution to code for
I) and the other from CTG to CTA (from requiring two nucleotide
substitutions to code for I to just one). There was no significant
subtype difference in the number of substitutions required to
mutate from L74L to L74I (P = 0.13).
Discussion
As we enter an era when dolutegravir-based ART will be used for tens
of millions of PLWH, it is vital to understand determinants of treat-
ment failure and drug resistance. To date, information on integrase
sequences by next-generation sequencing in subtypes dominating in
West Africa has been extremely limited. Recently, a series of VF
patients in a trial of the integrase inhibitor cabotegravir were found to
harbour L74I (a polymorphic mutation that is weakly selected for by
INSTI therapy) in addition to other major integrase inhibitor drug
resistance mutations. This prompted us to evaluate not only
major integrase inhibitor mutations, but also L74I.
Reassuringly, we found that major resistance mutations
to integrase inhibitors were very rare in this study population
that had extensive NRTI and NNRTI resistance following VF
with NNRTI-based regimens. One individual out of 115 had
both L74I and the signature dolutegravir mutation R263K
detected by next-generation sequencing,23–26 though R263K
was a minority variant.
Table 1. Participant characteristics at first-line ART failure
All, N = 115 L74I present at >2% frequency, N = 46 L74I not detected, N = 69 Pa
Age (years), median (IQR) 30 (26–39) 32 (27–40) 30 (26–37) 0.28
<30, n (%) 48 (41.7) 14 (30.4) 34 (49.3) 0.05
>30, n (%) 67 (58.2) 32 (69.6) 35 (50.7)
Sex, n (%)
female 78 (67.8) 33 (71.7) 45 (65.2) 0.46
male 37 (32.2) 13 (28.3) 24 (34.8)
CD4 cell count (cells/mm3), median (IQR)b 142 (64–246) 153 (112–256) 133 (47–214) 0.06
<200, n (%) 77 (67.5) 28 (60.9) 49 (72.1) 0.21
>200, n (%) 37 (32.5) 18 (39.1) 19 (27.9)
HIV-1 RNA (log10 copies/mL), median (IQR)
b 4.94 (4.36–5.37) 4.83 (4.40–5.19) 5.00 (4.35–5.48) 0.09
<100 000, n (%) 65 (57.5) 31 (68.9) 34 (50.0) 0.05
>100 000, n (%) 48 (42.5) 14 (31.1) 34 (50.0)
Time on ART (months), median (IQR) 32.9 (19.0–49.6) 34.7 (19.0–46.2) 31.0 (18.8–50.5) 0.74
<1 year, n (%) 16 (13.9) 5 (10.9) 11 (15.9) 0.74
1–2 years, n (%) 25 (21.7) 11 (23.9) 14 (20.3)
2–3 years, n (%) 24 (20.9) 9 (19.6) 15 (21.7)
3–4 years, n (%) 20 (17.4) 10 (21.7) 10 (14.5)
>4 years, n (%) 30 (26.1) 11 (23.9) 19 (27.5)
HIV-1 subtype, n (%)
CRF02_AG 68 (59.1) 20 (43.5) 48 (69.6) 0.005
G 47 (40.9) 26 (56.5) 21 (30.4)
av2 or Mann–Whitney test, as appropriate.
bMissing data: CD4 cell count, 1 (L74I, 0; no L74I, 1); and HIV-1 RNA, 2 (L74I, 1; no L74I, 1).
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We found over a third of the integrase inhibitor-naive HIV-
positive participants in our study had the integrase L74I
mutation and that L74I was more common in HIV-1 subtype G
than CRF02_AG. This is the first time that such a high prevalence
of L74I mutations has been reported in West African G and
AG subtypes, with potential implications for the effectiveness
of dolutegravir, which is now being rolled out as part of the
first-line treatment in this setting, where there is less frequent
viral load monitoring and less access to genotypic resistance
testing.
Table 2. Participants with L74I and longitudinal sampling
Participant Subtype Sample ART line Viral load (copies/mL)
pol drug resistance mutations
(consensus sequence)
Integrase
L74I (%)
Integrase L74I
evolution
1 G 1 first 373 000 RT: M184V, K103N, Y318F 99.2 fixed majority
2 first 274 500 RT: K70R, M184V, K219Q, K103N, Y318F 88.4
2 G 1 first 532 000 RT: D67N, K70R, M184V, T215I, K219E, Y181C 99.6 fixed majority
2 second 36 000 RT: M184V, T215F, K219E, V179VLM, Y181C 90.9
3 G 1 first 29 000 RT: K70R, M184V, A98G, V108I, Y181C 95.6 fixed majority
2 second 4300 RT: K70R, M184V, T215F, K219Q, V108I, Y181C,
N348I
93.3
4 G 1 first 25 000 RT: M184V, K103N, K238T 99.5 fixed majority
2 second 1 450 000 none 99.8
5 G 1 first 370 000 RT: M184V, K103N, Y318F 99.2 fixed majority
2 second 275 000 RT: K70R, M184V, K219Q, K103N, Y318F 88.4
6 G 1 first 28 000 RT: M41L, D67N, T69D, K70R, V75M, M184V, T215F,
K219Q, A98G, K103N, V179E, K238T, Y318F
85.5 fixed majority
2 first 63 000 RT: M41L, D67N, T69D, K70R, V75M, M184V, T215F,
K219Q, A98G, K103N, V179E, K238T, Y318F
99.1
3 first 442 000 RT: M41L, D67N, T69D, K70R, V75M, M184V,
T215FL, K219Q, A98G, K103N, V179E, K238T,
Y318F
98.9
4 second 5800 RT: M41L, D67N, T69D, V75M, M184V, T215IV,
K219Q, A98G, K103N, V179E, K238T, Y318F
97.7
7 AG 1 first 48 000 RT: M184V, K103N, P225H 98.1 fixed majority
2 second 11 000 RT: M184V, K103N 94.7
8 AG 1 first 241 000 RT: K103N, H221Y 99.5 fixed majority
2 first 250 000 RT: Y181C, H221Y 99.0
3 second 4400 RT: K103N, Y181C, H221Y 92.3
9 G 1 first 272 000 RT: K70E, Y115F, M184V, Y181C, G190A, H221Y 90.0 revertant majority
2 second 24 000 RT: K70E, Y115F, M184V, Y181C, G190A, H221YPro:
M46I, I54V, V82S, L24I, L33F
ND
10 G 1 first 59 000 RT: K65R, M184V, K219E, Y181C, H221Y 2.2 fixed minority
2 second 1700 RT: K65R, M184V, K219E, Y181C, H221YPro: I54V,
V82A, L10F
2.7
11 G 1 second 5700 RT: M41L, V75I, M184V, T215F, K101H, G190A,
N348I
3.6 fixed minority
2 second 384 000 RT: M41L, D67N, V75I, M184V, T215F, G190A,
N348I
2.1
12 AG 1 second 5700 RT: M41L, V75I, M184V, T215F, K101H, G190A,
N348I
3.6 fixed minority
2 second 384 000 RT: M41L, D67N, V75I, T215F, G190A, N348I 2.1
13 G 1 first 20 000 RT: M184V, K101E, G190A ND emergent minority
2 second 118 000 none 8.1
14 G 1 first 77 000 RT: M41L, E44D, D67N, K70R, L74V, M184V, T215Y,
Y181C, G190A, N348IPro: L90M
39.2 revertant minority
2 second 56 000 RT: M41L, E44D, D67N, T69D, K70R, L74V, M184V,
T215Y, Y181C, G190A, N348IPro: M46I, 154V,
V82A, L90M
2.4
RT, reverse transcriptase; Pro, protease; AG, CRF02_AG; ND, not detected.
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Uniquely, in this study we were able to assess the frequency of
viral variants with L74I in longitudinal samples from multiple indi-
viduals. In most cases there was no change in variant frequencies,
consistent with L74I being transmitted between individuals
following a founder effect and L74I reverting rarely, even during
second-line ART failure. This would be consistent with a lack of
fitness cost of L74I in the absence of drug pressure.
A limitation of this study was that our patient group were
mainly ART-experienced and as such there may be a different
prevalence of L74I in treatment-naive individuals. Furthermore, al-
though L74I was associated with VF in two studies including the
long-acting injectable cabotegravir, it is not known whether L74I
contributed to VF or what the impact on dolutegravir might be.
In vitro studies are needed to determine whether L74I facilitates
high-level INSTI resistance in non-B subtypes and clinical studies
are necessary to determine whether L74I at baseline impacts clin-
ical or virological outcomes on integrase inhibitors, even when
short-term outcomes in cross-sectional studies appear favourable.
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